PMID- 36780882
OWN - NLM
STAT- MEDLINE
DCOM- 20231226
LR  - 20240102
IS  - 1423-0216 (Electronic)
IS  - 1021-7401 (Linking)
VI  - 30
IP  - 1
DP  - 2023
TI  - Aberrant Dendritic Cell Subsets in Patients with Myasthenia Gravis and Related 
      Clinical Features.
PG  - 69-80
LID - 10.1159/000529626 [doi]
AB  - INTRODUCTION: Dendritic cells (DCs) play critical roles in the pathogenesis of 
      myasthenia gravis (MG), and a series of DC-based experimental strategies for MG 
      have recently been developed. However, the definite roles of different DC subsets 
      in the mechanism of MG have scarcely been covered by previous studies. The 
      present study aimed to investigate the levels of three main DC subsets, 
      plasmacytoid DCs (pDCs) (CD303 positive) and two distinct subsets of conventional 
      DCs (cDCs), namely CD1c+ cDCs and CD141+ cDCs, in MG patients and analyze related 
      clinical features. METHODS: From January 2016 to December 2020, 160 newly 
      diagnosed MG patients and matched healthy controls (n = 160) were included in the 
      study, and their clinical data were collected. The blood samples from MG patients 
      before treatment and controls were collected for flow cytometry analysis. A total 
      of 14 MG thymoma, 24 control thymoma, and 3 thymic cysts were used to immunostain 
      the DC subsets. RESULTS: The flow cytometry analysis showed a significantly 
      higher frequency of circulating pDCs, CD1c+ cDCs, and CD141+ cDCs in MG patients 
      than in healthy controls (p < 0.001 for all). Patients with early-onset MG 
      (<50 years old) had a lower frequency of circulating pDCs but a higher 
      frequency of circulating CD1c+ cDCs than those with late-onset MG (>/=50 years old) 
      (p = 0.014 and p = 0.025, respectively). The frequency of circulating pDCs was 
      positively associated with the clinical severity of late-onset MG patients (r = 
      0.613, p < 0.001). 64.3% (9/14) of MG thymoma is of type B2 under the World 
      Health Organization classification, which is higher than that in control thymoma 
      (33.3%, 8/24) (p = 0.019). For type B2 thymoma, there were significantly more 
      pDCs but fewer CD1c+ cDCs in MG thymoma than in the controls. CONCLUSION: The 
      distribution of aberrant pDCs, CD1c+ cDCs, and CD141+ cDCs in MG patients 
      displayed age- and thymoma-related differences, which may contribute to the 
      impaired immune tolerance and lead to the onset of MG.
CI  - (c) 2023 The Author(s). Published by S. Karger AG, Basel.
FAU - Song, Yan
AU  - Song Y
AD  - Department of Neurology, The Second Hospital of Shandong University, Jinan, 
      China.
AD  - Department of Neurology, Affiliated Hospital of Jining Medical University, 
      Jining, China.
FAU - Xing, Chunye
AU  - Xing C
AD  - Department of Neurology, Affiliated Hospital of Jining Medical University, 
      Jining, China.
FAU - Lu, Tianyang
AU  - Lu T
AD  - Department of Public Health, Monash University, Melbourne, Victoria, Australia.
FAU - Liu, Chen
AU  - Liu C
AD  - Department of Neurology, Affiliated Hospital of Jining Medical University, 
      Jining, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Pathology, Affiliated Hospital of Jining Medical University, 
      Jining, China.
FAU - Wang, Shaoqiang
AU  - Wang S
AD  - Department of Thoracic Surgery, Affiliated Hospital of Jining Medical University, 
      Jining Medical University, Jining, China.
FAU - Feng, Xungang
AU  - Feng X
AD  - Department of Neurology, Affiliated Hospital of Jining Medical University, 
      Jining, China.
FAU - Bi, Jianzhong
AU  - Bi J
AD  - Department of Neurology, The Second Hospital of Shandong University, Jinan, 
      China.
FAU - Wang, Qian
AU  - Wang Q
AD  - Department of Neurology, The First Hospital of Tsinghua University, Beijing, 
      China.
FAU - Lai, Chao
AU  - Lai C
AD  - Department of Neurology, The Second Hospital of Shandong University, Jinan, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20230213
PL  - Switzerland
TA  - Neuroimmunomodulation
JT  - Neuroimmunomodulation
JID - 9422763
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - *Thymoma/metabolism
MH  - *Myasthenia Gravis
MH  - Immune Tolerance
MH  - *Thymus Neoplasms/metabolism
MH  - Dendritic Cells/metabolism
OTO - NOTNLM
OT  - Clinical features
OT  - Dendritic cells
OT  - Myasthenia gravis
OT  - Thymoma
EDAT- 2023/02/14 06:00
MHDA- 2023/12/26 06:41
CRDT- 2023/02/13 18:23
PHST- 2022/05/19 00:00 [received]
PHST- 2022/12/13 00:00 [accepted]
PHST- 2023/12/26 06:41 [medline]
PHST- 2023/02/14 06:00 [pubmed]
PHST- 2023/02/13 18:23 [entrez]
AID - 000529626 [pii]
AID - 10.1159/000529626 [doi]
PST - ppublish
SO  - Neuroimmunomodulation. 2023;30(1):69-80. doi: 10.1159/000529626. Epub 2023 Feb 
      13.